---
title: A phase Ib/II trial of capmatinib plus spartalizumab <em>vs.</em> spartalizumab
  alone in patients with pretreated hepatocellular carcinoma
date: '2024-04-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38617599/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240415180531&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Capmatinib at 400 mg bid plus spartalizumab 300 mg q3w was
  established as the RP2D, with manageable toxicities and no significant safety signals,
  but the combination did not show superior clinical activity compared with spartalizumab
  single-agent treatment in patients with advanced HCC who had previously been treated
  with ...'
disable_comments: true
---
CONCLUSION: Capmatinib at 400 mg bid plus spartalizumab 300 mg q3w was established as the RP2D, with manageable toxicities and no significant safety signals, but the combination did not show superior clinical activity compared with spartalizumab single-agent treatment in patients with advanced HCC who had previously been treated with ...